Background We aimed to evaluate the effect of prophylactic nebivolol use on prevention of
antracycline-induced cardiotoxicity in breast cancer patients. Methods In this small …

Anthracycline is a commonly prescribed antineoplastic agent. As a consequence of the
growing number of cancer survivors, the incidence of anthracycline-induced cardiotoxicity is …

Background: Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Prevention
with β-blockers remains controversial. Objectives: This prospective, randomized, double …

Purpose: Anthracyclines (ANTs) are a class of active antineoplastic agents with
topoisomerase-interacting activity that are considered the most active agents for the …

Anthracyclines are among the most active drugs in breast cancer patients. We planned to
evaluate the early and 2-year modification of left ventricular ejection fraction (LVEF) and the …

Background Troponin changes over time have been suggested to allow for an early
diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin …

Anthracyclines are highly effective chemotherapeutic agents, used for a wide variety of
malignancies. Cardiotoxicity is a well‑recognized side effect of anthracycline therapy that …

Objectives: The aim of this study was to determine the protective effect of carvedilol in
anthracycline (ANT)-induced cardiomyopathy (CMP). Background: Despite its broad …

Anthracycline (ANT) is a topoisomerase-interacting agent that is used in most malignancy
treatments. We investigated the efficacy of enalapril (angiotensin-converting enzyme …

Aims The protective effect of beta‐blockers, ACE inhibitors, and ARBs on anthracycline
cardiotoxicity has already been demonstrated, but the effect of aldosterone antagonism …